Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)
This study is currently recruiting participants.
Verified December 2012 by University Hospital Muenster
Sponsor:
University Hospital Muenster
Collaborator:
Boehringer Ingelheim Pharmaceuticals
Information provided by (Responsible Party):
University Hospital Muenster
ClinicalTrials.gov Identifier:
NCT01488344
First received: November 15, 2011
Last updated: December 19, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Estimated Primary Completion Date: | November 2014 (Final data collection date for primary outcome measure) |